An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.
The positive data from a phase 2 trial of omaveloxolone in neurodegenerative disorder Friedreich’s ataxia prompted a 34% increase in Reata’s share price after-hours, which added to earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback